| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Feeding | 14 | 2022 | 113 | 3.750 |
Why?
|
| Product Surveillance, Postmarketing | 7 | 2019 | 96 | 1.920 |
Why?
|
| Mothers | 6 | 2022 | 103 | 1.480 |
Why?
|
| Maternal Health Services | 3 | 2022 | 11 | 1.440 |
Why?
|
| Humans | 73 | 2022 | 17314 | 1.290 |
Why?
|
| United States | 36 | 2022 | 3866 | 1.200 |
Why?
|
| Infant Formula | 3 | 2016 | 9 | 1.120 |
Why?
|
| Infant | 22 | 2022 | 1161 | 1.110 |
Why?
|
| Female | 49 | 2022 | 12396 | 1.010 |
Why?
|
| Influenza Vaccines | 5 | 2022 | 292 | 1.010 |
Why?
|
| Chickenpox Vaccine | 3 | 2019 | 91 | 0.990 |
Why?
|
| Hospitals | 3 | 2018 | 71 | 0.990 |
Why?
|
| Executive Function | 7 | 2022 | 23 | 0.930 |
Why?
|
| Child | 22 | 2022 | 2403 | 0.870 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 4 | 2019 | 62 | 0.830 |
Why?
|
| Child, Preschool | 23 | 2022 | 1380 | 0.820 |
Why?
|
| Feeding Behavior | 4 | 2022 | 163 | 0.810 |
Why?
|
| Male | 36 | 2022 | 9804 | 0.800 |
Why?
|
| Trichomonas Infections | 1 | 2022 | 1 | 0.800 |
Why?
|
| Sex Offenses | 1 | 2022 | 9 | 0.790 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 54 | 0.770 |
Why?
|
| Hepatitis B | 1 | 2022 | 45 | 0.760 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2022 | 16 | 0.750 |
Why?
|
| Seizures, Febrile | 2 | 2019 | 42 | 0.710 |
Why?
|
| Maternal Behavior | 2 | 2018 | 12 | 0.700 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2022 | 59 | 0.700 |
Why?
|
| Population Surveillance | 7 | 2019 | 252 | 0.690 |
Why?
|
| Herpes Zoster | 1 | 2022 | 82 | 0.680 |
Why?
|
| Vaccines, Combined | 3 | 2019 | 80 | 0.650 |
Why?
|
| Infant, Newborn | 11 | 2020 | 805 | 0.650 |
Why?
|
| Pregnancy | 13 | 2022 | 1463 | 0.640 |
Why?
|
| Drug Monitoring | 1 | 2019 | 18 | 0.620 |
Why?
|
| Rubella | 1 | 2019 | 7 | 0.620 |
Why?
|
| Mumps | 1 | 2019 | 12 | 0.610 |
Why?
|
| Chickenpox | 1 | 2019 | 35 | 0.600 |
Why?
|
| Measles | 1 | 2019 | 24 | 0.600 |
Why?
|
| Influenza, Human | 3 | 2017 | 282 | 0.590 |
Why?
|
| Physicians | 1 | 2019 | 117 | 0.560 |
Why?
|
| Epidemiologic Research Design | 3 | 2013 | 18 | 0.560 |
Why?
|
| Adult | 17 | 2022 | 7500 | 0.550 |
Why?
|
| Campylobacter | 3 | 2007 | 3 | 0.550 |
Why?
|
| Campylobacter Infections | 3 | 2007 | 3 | 0.550 |
Why?
|
| Pediatric Obesity | 2 | 2017 | 88 | 0.530 |
Why?
|
| Adolescent | 16 | 2022 | 3538 | 0.530 |
Why?
|
| Public Opinion | 1 | 2016 | 3 | 0.520 |
Why?
|
| Poliovirus Vaccine, Inactivated | 2 | 2014 | 21 | 0.500 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 23 | 0.500 |
Why?
|
| Dietary Supplements | 1 | 2016 | 85 | 0.500 |
Why?
|
| Vaccines | 5 | 2022 | 220 | 0.490 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2016 | 215 | 0.490 |
Why?
|
| Cohort Studies | 14 | 2022 | 2514 | 0.490 |
Why?
|
| Health Care Surveys | 5 | 2020 | 211 | 0.470 |
Why?
|
| Vaccination | 5 | 2022 | 688 | 0.470 |
Why?
|
| Statistics as Topic | 2 | 2013 | 56 | 0.470 |
Why?
|
| Directive Counseling | 1 | 2015 | 23 | 0.460 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2007 | 16 | 0.450 |
Why?
|
| Patient Discharge | 2 | 2018 | 153 | 0.440 |
Why?
|
| Resilience, Psychological | 1 | 2014 | 11 | 0.440 |
Why?
|
| Weight Reduction Programs | 1 | 2015 | 49 | 0.430 |
Why?
|
| Logistic Models | 6 | 2020 | 879 | 0.420 |
Why?
|
| Social Environment | 1 | 2014 | 85 | 0.420 |
Why?
|
| Observational Studies as Topic | 3 | 2022 | 47 | 0.410 |
Why?
|
| Longitudinal Studies | 10 | 2022 | 674 | 0.410 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 62 | 0.400 |
Why?
|
| Haemophilus Vaccines | 1 | 2013 | 19 | 0.400 |
Why?
|
| Mortality | 1 | 2013 | 116 | 0.390 |
Why?
|
| Vaccines, Conjugate | 2 | 2013 | 59 | 0.390 |
Why?
|
| Immunization Programs | 2 | 2009 | 65 | 0.380 |
Why?
|
| Equipment Safety | 1 | 2011 | 2 | 0.370 |
Why?
|
| Intention | 3 | 2022 | 30 | 0.360 |
Why?
|
| Ethnic Groups | 4 | 2021 | 451 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 143 | 0.360 |
Why?
|
| Postnatal Care | 4 | 2022 | 20 | 0.360 |
Why?
|
| Parasympatholytics | 1 | 2011 | 1 | 0.360 |
Why?
|
| Escherichia coli O157 | 1 | 2011 | 1 | 0.360 |
Why?
|
| Shiga Toxins | 1 | 2011 | 1 | 0.360 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2011 | 2 | 0.360 |
Why?
|
| Escherichia coli Infections | 1 | 2011 | 6 | 0.360 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2022 | 29 | 0.360 |
Why?
|
| Calcinosis | 3 | 2006 | 35 | 0.350 |
Why?
|
| Young Adult | 7 | 2021 | 2465 | 0.350 |
Why?
|
| Aged | 10 | 2022 | 6084 | 0.340 |
Why?
|
| Atherosclerosis | 2 | 2014 | 52 | 0.340 |
Why?
|
| Adolescent Behavior | 2 | 2022 | 121 | 0.330 |
Why?
|
| Infant Care | 2 | 2020 | 7 | 0.320 |
Why?
|
| Hepatitis A Vaccines | 1 | 2009 | 15 | 0.320 |
Why?
|
| Coronary Artery Disease | 3 | 2005 | 112 | 0.320 |
Why?
|
| Time Factors | 5 | 2018 | 1039 | 0.320 |
Why?
|
| Hepatitis B Vaccines | 1 | 2009 | 44 | 0.310 |
Why?
|
| Primary Health Care | 1 | 2015 | 726 | 0.300 |
Why?
|
| Health Personnel | 2 | 2022 | 126 | 0.290 |
Why?
|
| Community-Acquired Infections | 1 | 2008 | 20 | 0.290 |
Why?
|
| Food Service, Hospital | 1 | 2008 | 1 | 0.290 |
Why?
|
| Foodborne Diseases | 1 | 2008 | 5 | 0.290 |
Why?
|
| Food Handling | 1 | 2008 | 6 | 0.290 |
Why?
|
| Homes for the Aged | 1 | 2008 | 6 | 0.290 |
Why?
|
| Pneumococcal Infections | 1 | 2008 | 44 | 0.290 |
Why?
|
| Nursing Homes | 1 | 2008 | 10 | 0.280 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2415 | 0.280 |
Why?
|
| Pneumonia | 1 | 2008 | 49 | 0.280 |
Why?
|
| Ciprofloxacin | 2 | 2004 | 2 | 0.280 |
Why?
|
| Pneumococcal Vaccines | 1 | 2008 | 68 | 0.280 |
Why?
|
| Anti-Infective Agents | 2 | 2004 | 13 | 0.270 |
Why?
|
| Electronic Health Records | 2 | 2014 | 704 | 0.270 |
Why?
|
| Feeding and Eating Disorders | 2 | 2017 | 16 | 0.270 |
Why?
|
| Poultry Diseases | 1 | 2007 | 1 | 0.270 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 5 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2005 | 203 | 0.270 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2019 | 93 | 0.260 |
Why?
|
| Multivariate Analysis | 3 | 2018 | 535 | 0.260 |
Why?
|
| Medication Adherence | 1 | 2009 | 235 | 0.260 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2020 | 88 | 0.260 |
Why?
|
| Databases, Factual | 3 | 2013 | 304 | 0.260 |
Why?
|
| Sphingomyelins | 1 | 2006 | 1 | 0.250 |
Why?
|
| Zika Virus Infection | 2 | 2016 | 3 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 1282 | 0.250 |
Why?
|
| Bias | 2 | 2020 | 96 | 0.240 |
Why?
|
| Animals | 5 | 2016 | 280 | 0.240 |
Why?
|
| Durapatite | 1 | 2005 | 1 | 0.240 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 1 | 0.240 |
Why?
|
| Risk Factors | 8 | 2017 | 3258 | 0.240 |
Why?
|
| Nutritional Status | 2 | 2022 | 32 | 0.230 |
Why?
|
| Health Promotion | 2 | 2018 | 279 | 0.230 |
Why?
|
| Models, Statistical | 3 | 2014 | 170 | 0.230 |
Why?
|
| Risk Assessment | 5 | 2018 | 1076 | 0.230 |
Why?
|
| Odds Ratio | 4 | 2018 | 640 | 0.230 |
Why?
|
| Diarrhea | 1 | 2004 | 12 | 0.220 |
Why?
|
| Demography | 3 | 2016 | 93 | 0.220 |
Why?
|
| Immunization Schedule | 3 | 2014 | 124 | 0.220 |
Why?
|
| Middle Aged | 11 | 2021 | 7836 | 0.220 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2020 | 6 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 605 | 0.200 |
Why?
|
| Prevalence | 5 | 2015 | 840 | 0.200 |
Why?
|
| Child Development | 2 | 2014 | 53 | 0.200 |
Why?
|
| HIV | 1 | 2022 | 26 | 0.200 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 1280 | 0.200 |
Why?
|
| Research Design | 4 | 2016 | 336 | 0.200 |
Why?
|
| Obesity | 2 | 2021 | 814 | 0.200 |
Why?
|
| Pericarditis | 1 | 2022 | 11 | 0.190 |
Why?
|
| Myocarditis | 1 | 2022 | 14 | 0.190 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.190 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 1925 | 0.190 |
Why?
|
| Narcolepsy | 1 | 2022 | 9 | 0.190 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.190 |
Why?
|
| Confounding Factors (Epidemiology) | 3 | 2012 | 84 | 0.190 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 384 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 15 | 0.190 |
Why?
|
| Case-Control Studies | 5 | 2020 | 1098 | 0.190 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 36 | 0.190 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 169 | 0.180 |
Why?
|
| Public Health | 3 | 2009 | 83 | 0.180 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2021 | 1 | 0.180 |
Why?
|
| Adolescent Health | 1 | 2021 | 6 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 151 | 0.180 |
Why?
|
| Managed Care Programs | 2 | 2013 | 300 | 0.180 |
Why?
|
| Tobacco Products | 1 | 2021 | 14 | 0.170 |
Why?
|
| Vaping | 1 | 2021 | 19 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 109 | 0.170 |
Why?
|
| Child Health | 1 | 2021 | 39 | 0.170 |
Why?
|
| Database Management Systems | 1 | 2020 | 14 | 0.170 |
Why?
|
| Milk, Human | 2 | 2020 | 7 | 0.170 |
Why?
|
| Medicare | 1 | 2022 | 192 | 0.170 |
Why?
|
| Problem Behavior | 1 | 2020 | 2 | 0.170 |
Why?
|
| Stillbirth | 1 | 2020 | 29 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2014 | 1226 | 0.170 |
Why?
|
| Child Behavior Disorders | 1 | 2020 | 16 | 0.170 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 52 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 302 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 701 | 0.170 |
Why?
|
| Propensity Score | 1 | 2020 | 76 | 0.170 |
Why?
|
| Body Mass Index | 3 | 2017 | 937 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2021 | 118 | 0.160 |
Why?
|
| Poverty | 2 | 2021 | 168 | 0.160 |
Why?
|
| Insurance, Health | 1 | 2021 | 170 | 0.160 |
Why?
|
| Food Packaging | 1 | 2019 | 2 | 0.160 |
Why?
|
| Recommended Dietary Allowances | 1 | 2019 | 2 | 0.160 |
Why?
|
| Infant Food | 1 | 2019 | 7 | 0.160 |
Why?
|
| Nutritive Value | 1 | 2019 | 11 | 0.160 |
Why?
|
| Dietary Sugars | 1 | 2019 | 6 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 437 | 0.160 |
Why?
|
| Continental Population Groups | 2 | 2021 | 286 | 0.160 |
Why?
|
| Databases, Pharmaceutical | 1 | 2019 | 6 | 0.160 |
Why?
|
| Pediatricians | 1 | 2019 | 14 | 0.150 |
Why?
|
| Energy Intake | 1 | 2019 | 98 | 0.150 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2018 | 2 | 0.150 |
Why?
|
| Infertility, Female | 1 | 2018 | 11 | 0.150 |
Why?
|
| Hospitals, Maternity | 1 | 2018 | 2 | 0.150 |
Why?
|
| Rooming-in Care | 1 | 2018 | 1 | 0.150 |
Why?
|
| Health Facilities | 1 | 2018 | 16 | 0.140 |
Why?
|
| Selection Bias | 1 | 2017 | 16 | 0.140 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 14 | 0.140 |
Why?
|
| Communicable Disease Control | 1 | 2017 | 19 | 0.140 |
Why?
|
| Extraversion (Psychology) | 1 | 2017 | 1 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 425 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2018 | 157 | 0.140 |
Why?
|
| Mother-Child Relations | 1 | 2017 | 13 | 0.130 |
Why?
|
| Overweight | 2 | 2016 | 266 | 0.130 |
Why?
|
| Hotlines | 1 | 2017 | 10 | 0.130 |
Why?
|
| Cognition | 2 | 2020 | 81 | 0.130 |
Why?
|
| Oral Health | 1 | 2017 | 17 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 310 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2017 | 35 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 2 | 2009 | 69 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2016 | 34 | 0.130 |
Why?
|
| Lactation | 1 | 2016 | 34 | 0.120 |
Why?
|
| Incidence | 4 | 2022 | 1266 | 0.120 |
Why?
|
| Anxiety | 1 | 2017 | 154 | 0.120 |
Why?
|
| Poisson Distribution | 2 | 2013 | 85 | 0.120 |
Why?
|
| Chickens | 2 | 2007 | 6 | 0.120 |
Why?
|
| Food Microbiology | 2 | 2005 | 2 | 0.120 |
Why?
|
| Georgia | 1 | 2015 | 14 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 367 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 1 | 0.110 |
Why?
|
| Serial Learning | 1 | 2014 | 1 | 0.110 |
Why?
|
| Brachial Artery | 1 | 2014 | 5 | 0.110 |
Why?
|
| Vasodilation | 1 | 2014 | 6 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2014 | 4 | 0.110 |
Why?
|
| Seizures | 1 | 2014 | 28 | 0.110 |
Why?
|
| Mental Recall | 1 | 2014 | 29 | 0.110 |
Why?
|
| African Americans | 1 | 2017 | 439 | 0.110 |
Why?
|
| Biometry | 1 | 2014 | 14 | 0.110 |
Why?
|
| Algorithms | 3 | 2017 | 223 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2017 | 356 | 0.110 |
Why?
|
| Safety | 1 | 2014 | 43 | 0.110 |
Why?
|
| Inflammation | 1 | 2014 | 63 | 0.110 |
Why?
|
| Epidemiologic Factors | 1 | 2013 | 3 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 197 | 0.100 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2006 | 10 | 0.100 |
Why?
|
| Biomarkers | 1 | 2014 | 307 | 0.100 |
Why?
|
| Inhibition (Psychology) | 1 | 2012 | 1 | 0.100 |
Why?
|
| Whooping Cough | 1 | 2013 | 65 | 0.100 |
Why?
|
| Age Factors | 4 | 2019 | 878 | 0.100 |
Why?
|
| Depression | 1 | 2017 | 486 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 78 | 0.100 |
Why?
|
| Washington | 1 | 2013 | 384 | 0.100 |
Why?
|
| Adamantane | 1 | 2012 | 3 | 0.090 |
Why?
|
| Dipeptides | 1 | 2012 | 3 | 0.090 |
Why?
|
| Device Approval | 1 | 2011 | 2 | 0.090 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2011 | 3 | 0.090 |
Why?
|
| Health Services | 1 | 2013 | 110 | 0.090 |
Why?
|
| Biostatistics | 1 | 2011 | 11 | 0.090 |
Why?
|
| Data Mining | 1 | 2011 | 16 | 0.090 |
Why?
|
| Hypertension | 1 | 2016 | 469 | 0.090 |
Why?
|
| Diphenoxylate | 1 | 2011 | 1 | 0.090 |
Why?
|
| Loperamide | 1 | 2011 | 1 | 0.090 |
Why?
|
| United States Food and Drug Administration | 2 | 2012 | 32 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 496 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 293 | 0.090 |
Why?
|
| Drug Utilization | 2 | 2013 | 121 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 532 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 312 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 120 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2012 | 270 | 0.080 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 224 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 664 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 250 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 99 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 287 | 0.080 |
Why?
|
| Consumer Product Safety | 1 | 2008 | 1 | 0.070 |
Why?
|
| Food Irradiation | 1 | 2008 | 1 | 0.070 |
Why?
|
| Medicaid | 1 | 2009 | 189 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2008 | 21 | 0.070 |
Why?
|
| Age Distribution | 1 | 2008 | 239 | 0.070 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 5 | 0.070 |
Why?
|
| Policy Making | 1 | 2007 | 13 | 0.070 |
Why?
|
| Data Collection | 1 | 2008 | 238 | 0.070 |
Why?
|
| Hispanic Americans | 2 | 2020 | 375 | 0.070 |
Why?
|
| Carotid Arteries | 1 | 2006 | 8 | 0.060 |
Why?
|
| Coronary Vessels | 1 | 2006 | 11 | 0.060 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 2 | 2016 | 32 | 0.060 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2006 | 2 | 0.060 |
Why?
|
| Shigella | 1 | 2006 | 2 | 0.060 |
Why?
|
| Shigella flexneri | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dysentery, Bacillary | 1 | 2005 | 2 | 0.060 |
Why?
|
| Lycopersicon esculentum | 1 | 2005 | 4 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 146 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2006 | 52 | 0.060 |
Why?
|
| beta-Lactamases | 1 | 2005 | 2 | 0.060 |
Why?
|
| beta-Lactam Resistance | 1 | 2005 | 2 | 0.060 |
Why?
|
| Enterobacteriaceae | 1 | 2005 | 3 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2005 | 6 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 37 | 0.060 |
Why?
|
| Phantoms, Imaging | 1 | 2005 | 5 | 0.060 |
Why?
|
| Calibration | 1 | 2005 | 7 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2009 | 1160 | 0.060 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 342 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2022 | 381 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2017 | 80 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 298 | 0.060 |
Why?
|
| Reaction Time | 2 | 2014 | 3 | 0.050 |
Why?
|
| Animals, Domestic | 1 | 2003 | 4 | 0.050 |
Why?
|
| Altruism | 1 | 2022 | 2 | 0.050 |
Why?
|
| Aggression | 1 | 2022 | 20 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 72 | 0.050 |
Why?
|
| Peer Group | 1 | 2022 | 54 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2021 | 3 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 36 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 99 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2014 | 1151 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 149 | 0.040 |
Why?
|
| Premature Birth | 1 | 2021 | 132 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 560 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 43 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2021 | 397 | 0.040 |
Why?
|
| Clinical Studies as Topic | 1 | 2017 | 1 | 0.040 |
Why?
|
| Health Surveys | 1 | 2018 | 245 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 28 | 0.030 |
Why?
|
| Dental Care | 1 | 2017 | 16 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2018 | 193 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2017 | 104 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 180 | 0.030 |
Why?
|
| Insect Vectors | 1 | 2016 | 1 | 0.030 |
Why?
|
| Culicidae | 1 | 2016 | 1 | 0.030 |
Why?
|
| Conjunctivitis | 1 | 2016 | 2 | 0.030 |
Why?
|
| Arthralgia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Exanthema | 1 | 2016 | 7 | 0.030 |
Why?
|
| Travel | 1 | 2016 | 10 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 55 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 22 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 65 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 804 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 54 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2017 | 154 | 0.030 |
Why?
|
| Dyslipidemias | 1 | 2016 | 56 | 0.030 |
Why?
|
| Schools | 1 | 2016 | 88 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 535 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 357 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2015 | 5 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2017 | 476 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 33 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 43 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 30 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 58 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2014 | 72 | 0.030 |
Why?
|
| Photic Stimulation | 1 | 2012 | 2 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 36 | 0.020 |
Why?
|
| Diabetes, Gestational | 1 | 2016 | 311 | 0.020 |
Why?
|
| Drug Approval | 1 | 2012 | 12 | 0.020 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 8 | 0.020 |
Why?
|
| Health Behavior | 1 | 2013 | 346 | 0.020 |
Why?
|
| Ampicillin Resistance | 1 | 2006 | 1 | 0.020 |
Why?
|
| Trimethoprim Resistance | 1 | 2006 | 1 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2006 | 1 | 0.020 |
Why?
|
| Ampicillin | 1 | 2006 | 2 | 0.020 |
Why?
|
| New York | 1 | 2005 | 17 | 0.020 |
Why?
|
| Restaurants | 1 | 2005 | 17 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 2005 | 1 | 0.020 |
Why?
|
| Quality Control | 1 | 2005 | 41 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 40 | 0.010 |
Why?
|
| Goals | 1 | 2002 | 27 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2002 | 72 | 0.010 |
Why?
|
| Disease Progression | 1 | 2002 | 259 | 0.010 |
Why?
|